Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-088766
Filing Date
2024-07-31
Accepted
2024-07-31 17:59:18
Documents
2
Period of Report
2024-07-29

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1537
2 EX-24 fate-ex24.htm EX-24 10010
  Complete submission text file 0000950170-24-088766.txt   12975
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Issuer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address
Mozaffarian Neelufar (Reporting) CIK: 0002031203 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36076 | Film No.: 241163333